endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.62751/2713-0177-2024-5-4-25endofocus-74Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL CASEМакропролактинемия: обзор литературы и представление клинических случаевMacroprolactinemia: A review of the literature and presentation of clinical caseshttps://orcid.org/0009-0000-9499-7857МельниковаП. М.MelnikovaP. M.

Мельникова Полина Михайловна – врач-ординатор

630089, г. Новосибирск, ул. Бориса Богаткова, д.175/1

Polina M. Melnikova, resident doctor

Novosibirsk

polinamel2506@gmail.comhttps://orcid.org/0000-0003-4095-0169РымарО. Д.RymarO. D.

Рымар Оксана Дмитриевна – д.м.н., главный научный сотрудник лаборатории клинико-популяционных и профилактических исследований терапевтических и эндокринных заболеваний 

630089, г. Новосибирск, ул. Бориса Богаткова, д.175/1

Oksana D. Rymar, D. Sci. (Med.), chief researcher of the laboratory of clinical-population and preventive studies of therapeutic and endocrine diseases 

Novosibirsk

Scopus Author ID: 24339174300

orymar23@gmail.comНаучно-исследовательский институт терапии и профилактической медицины - филиал Федерального государственного бюджетного научного учреждения «Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук» (НИИТПМ — филиал ИЦиГ СО РАН)Institute of Internal and Preventive Medicine – branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences20242512202454106112Copyright © Мельникова П.М., Рымар О.Д., 20252025Мельникова П.М., Рымар О.Д.Melnikova P.M., Rymar O.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/74

Макропролактинемия считается распространенной причиной гиперпролактинемии. Клиническая картина пациентов с макро- пролактинемией часто не имеет выраженных признаков синдрома гиперпролактинемии, а выполнение анализа на наличие макропролактина зачастую способно предотвратить назначение избыточных обследований и терапии для данной группы па- циентов. Однако на сегодняшний день нет однозначного понимания, действительно ли макропролактин обладает сниженной биологической активностью по сравнению с мономерной формой пролактина. Также в связи с аутоиммунной природой макро- пролактина актуальным представляется вопрос о возможной связи этого феномена с другими аутоиммунными патологиями. Цель данного обзора – проведение анализа электронных баз данных PubMed, eLIBRARY по соответствующим ключевым словам по теме макропролактинемия. Также в статье представлены два клинических случая макро- пролактинемии у пациенток с гиперпролактинемией.

Macroprolactinemia is considered to be a common cause of hyperprolactinemia. The clinical presentation of patients with macroprolactinemia often has lack of hyperprolactinemic symptoms, and performing a macroprolactin assay can prevent the prescription of unnecessary investigation and treatment. However, there is no definite understanding of whether macroprolactin actually has reduced biological activity compared to the monomeric form of prolactin. Also, due to the autoimmunity of macroprolactin, the question of the possible association of this phenomenon with other autoimmune diseases is relevant. The aim of this review is to analyze the electronic database PubMed, eLIBRARY for articles that included any of the related key words to analyze all the relevant literature on the topic of macroprolactinemia. Two clinical cases of macroprolactinemia in patients with hyperprolactinemia are presented as well.

макропролактингиперпролактинемияфеномен макропролактинемииmacroprolactinhyperprolactinemiamacroprolactinemiaCтатья подготовлена в рамках госзадания «Эпидемиологический мониторинг распространенных терапевтических заболеваний, их факторов риска и осложнений в Сибири для совершенствования подходов к их профилактике и рискометрии», 2024-2028 гг. (FWNR-2024-0002)The article was prepared within the framework of the state task “Epidemiological monitoring of common therapeutic diseases, their risk factors and complications in Siberia to improve approaches to their prevention and risk measurement”, 2024–2028 (FWNR-2024-0002)ReferencesCosta-Brito A.R., Gonçalves I., Santos C.R.A. The brain as a source and a target of prolactin in mammals. Neural Regen Res. 2022; 17(8): 1695–702. doi: 10.4103/1673-5374.332124.Costa-Brito A.R., Gonçalves I., Santos C.R.A. The brain as a source and a target of prolactin in mammals. Neural Regen Res. 2022; 17(8): 1695–702. doi: 10.4103/1673-5374.332124.Mousavi MJ, Alizadeh A, Ghotloo S. Interference of B lymphocyte tolerance by prolactin in rheumatic autoimmune diseases. Heliyon. 2023; 9(6): e16977. doi: 10.1016/j.heliyon.2023.e16977.Mousavi MJ, Alizadeh A, Ghotloo S. Interference of B lymphocyte tolerance by prolactin in rheumatic autoimmune diseases. Heliyon. 2023; 9(6): e16977. doi: 10.1016/j.heliyon.2023.e16977.Pirchio R, Graziadio C, Colao A et al. Metabolic effects of prolactin. Front Endocrinol (Lausanne). 2022; 13: 1015520. doi: 10.3389/fendo.2022.1015520.Pirchio R, Graziadio C, Colao A et al. Metabolic effects of prolactin. Front Endocrinol (Lausanne). 2022; 13: 1015520. doi: 10.3389/fendo.2022.1015520.Ramos-Martinez E, Ramos-Martínez I, Molina-Salinas G et al. The role of prolactin in central nervous system inflammation. Rev Neurosci. 2021; 32(3): 323–40. doi: 10.1515/revneuro-2020-0082.Ramos-Martinez E, Ramos-Martínez I, Molina-Salinas G et al. The role of prolactin in central nervous system inflammation. Rev Neurosci. 2021; 32(3): 323–40. doi: 10.1515/revneuro-2020-0082.Macotela Y, Ruiz-Herrera X, Vazquez-Carrillo DI et al. The beneficial metabolic actions of prolactin. Front Endocrinol (Lausanne). 2022; 13: 1001703. doi: 10.3389/fendo.2022.1001703.Macotela Y, Ruiz-Herrera X, Vazquez-Carrillo DI et al. The beneficial metabolic actions of prolactin. Front Endocrinol (Lausanne). 2022; 13: 1001703. doi: 10.3389/fendo.2022.1001703.Koniares K, Benadiva C, Engmann L et al. Macroprolactinemia: A mini-review and update on clinical practice. F S Rep. 2023; 4(3): 245–50. doi: 10.1016/j.xfre.2023.05л.005.Koniares K, Benadiva C, Engmann L et al. Macroprolactinemia: A mini-review and update on clinical practice. F S Rep. 2023; 4(3): 245–50. doi: 10.1016/j.xfre.2023.05л.005.Yang W, Guo Z, Zhou Y et al. Optimization of a screening method for macroprolactinemia. J Chromatogr B Analyt Technol Biomed Life Sci. 2021; 1175: 122723. doi: 10.1016/j.jchromb.2021.122723.Yang W, Guo Z, Zhou Y et al. Optimization of a screening method for macroprolactinemia. J Chromatogr B Analyt Technol Biomed Life Sci. 2021; 1175: 122723. doi: 10.1016/j.jchromb.2021.122723.Сарибекян А.Г., Петренко Д.А., Трухина Д.А. с соавт. Феномен макро-ТТГ у пациентов с первичным гипотиреозом в исходе аутоиммунного тиреоидита. Клиническая и экспериментальная тиреоидология. 2021; 17(4): 17–20. doi: 10.14341/ket12710.Сарибекян А.Г., Петренко Д.А., Трухина Д.А. с соавт. Феномен макро-ТТГ у пациентов с первичным гипотиреозом в исходе аутоиммунного тиреоидита. Клиническая и экспериментальная тиреоидология. 2021; 17(4): 17–20. doi: 10.14341/ket12710.Sharma LK, Dutta D, Sharma N et al. Prevalence of macroprolactinemia in people detected to have hyperprolactinemia. J Lab Physicians. 2021; 13(4): 353–57. doi: 10.1055/s-0041-1732490.Sharma LK, Dutta D, Sharma N et al. Prevalence of macroprolactinemia in people detected to have hyperprolactinemia. J Lab Physicians. 2021; 13(4): 353–57. doi: 10.1055/s-0041-1732490.Yu C, Fan F, Hu S et al. Evaluation of autoantibodies and immunoglobulin G subclasses in women with suspected macroprolactinemia. J Clin Lab Anal. 2020; 34(11): e23456. doi: 10.1002/jcla.23456.Yu C, Fan F, Hu S et al. Evaluation of autoantibodies and immunoglobulin G subclasses in women with suspected macroprolactinemia. J Clin Lab Anal. 2020; 34(11): e23456. doi: 10.1002/jcla.23456.Sostaric M, Bokulic A, Marijancevic D, Zec I. Optimizing laboratory defined macroprolactin algorithm. Biochem Med (Zagreb). 2019; 29(2): 020706. doi: 10.11613/BM.2019.020706.Sostaric M, Bokulic A, Marijancevic D, Zec I. Optimizing laboratory defined macroprolactin algorithm. Biochem Med (Zagreb). 2019; 29(2): 020706. doi: 10.11613/BM.2019.020706.Воротникова С.Ю., Дзеранова Л.К., Федорова Н.С. с соавт. Исследование уровня мономерного пролактина с использованием методики преципитации с полиэтиленгликолем и технологии TRACE. Клиническая лабораторная диагностика. 2021; 66(2): 69–74. doi: 10.51620/0869-2084-2021-66-2-69-74.Воротникова С.Ю., Дзеранова Л.К., Федорова Н.С. с соавт. Исследование уровня мономерного пролактина с использованием методики преципитации с полиэтиленгликолем и технологии TRACE. Клиническая лабораторная диагностика. 2021; 66(2): 69–74. doi: 10.51620/0869-2084-2021-66-2-69-74.Hu Y, Ni J, Zhang B et al. Establishment of reference intervals of monomeric prolactin to identify macroprolactinemia in Chinese patients with increased total prolactin. BMC Endocr Disord. 2021; 21(1): 197. doi: 10.1186/s12902-021-00861-zHu Y, Ni J, Zhang B et al. Establishment of reference intervals of monomeric prolactin to identify macroprolactinemia in Chinese patients with increased total prolactin. BMC Endocr Disord. 2021; 21(1): 197. doi: 10.1186/s12902-021-00861-zМельниченко Г.А., Гончаров Н.П., Дзеранова Л.К. с соавт. Клинические и лабораторные аспекты исследования изоформ пролактина методами ПЭГпреципитации и ультрафильтрации. Проблемы эндокринологии. 2010; 56(1): 19–25. doi: 10.14341/probl201056119-25.Мельниченко Г.А., Гончаров Н.П., Дзеранова Л.К. с соавт. Клинические и лабораторные аспекты исследования изоформ пролактина методами ПЭГпреципитации и ультрафильтрации. Проблемы эндокринологии. 2010; 56(1): 19–25. doi: 10.14341/probl201056119-25.Rufo E, Martinez-Couselo S, Jimenez-Anon L et al. Marked geographical variation in the prevalence of macroprolactinemia. Clin Chem Lab Med. 2021; 60(3): 71–74. doi: 10.1515/cclm-2021-1124.Rufo E, Martinez-Couselo S, Jimenez-Anon L et al. Marked geographical variation in the prevalence of macroprolactinemia. Clin Chem Lab Med. 2021; 60(3): 71–74. doi: 10.1515/cclm-2021-1124.Che Soh NAA, Yaacob NM, Omar J et al. Global prevalence of macroprolactinemia among patients with hyperprolactinemia: A systematic review and meta-analysis. Int J Environ Res Public Health. 2020; 17(21): 8199. doi: 10.3390/ijerph17218199.Che Soh NAA, Yaacob NM, Omar J et al. Global prevalence of macroprolactinemia among patients with hyperprolactinemia: A systematic review and meta-analysis. Int J Environ Res Public Health. 2020; 17(21): 8199. doi: 10.3390/ijerph17218199.Chang S, Copperman AB. New insights into human prolactin pathophysiology: Genomics and beyond. Curr Opin Obstet Gynecol. 2019; 31(4): 207–11. doi: 10.1097/GCO.0000000000000545.Chang S, Copperman AB. New insights into human prolactin pathophysiology: Genomics and beyond. Curr Opin Obstet Gynecol. 2019; 31(4): 207–11. doi: 10.1097/GCO.0000000000000545.Isik S, Berker D, Tutuncu YA et al. Clinical and radiological findings in macroprolactinemia. Endocrine. 2012; 41(2): 327–33. doi: 10.1007/s12020-011-9576-9.Isik S, Berker D, Tutuncu YA et al. Clinical and radiological findings in macroprolactinemia. Endocrine. 2012; 41(2): 327–33. doi: 10.1007/s12020-011-9576-9.Kalsi AK, Halder A, Jain M et al. Prevalence and reproductive manifestations of macroprolactinemia. Endocrine. 2019; 63(2): 332–40. doi: 10.1007/s12020-018-1770-6.Kalsi AK, Halder A, Jain M et al. Prevalence and reproductive manifestations of macroprolactinemia. Endocrine. 2019; 63(2): 332–40. doi: 10.1007/s12020-018-1770-6.Krysiak R, Kowalcze K, Okopien B. Macroprolactinemia attenuates the impact of levothyroxine on hypothalamic-pituitary-thyroid axis activity and thyroid autoimmunity in women with autoimmune hypothyroidism. J Clin Pharmacol. 2020; 60(11): 1496–501. doi: 10.1002/jcph.1655.Krysiak R, Kowalcze K, Okopien B. Macroprolactinemia attenuates the impact of levothyroxine on hypothalamic-pituitary-thyroid axis activity and thyroid autoimmunity in women with autoimmune hypothyroidism. J Clin Pharmacol. 2020; 60(11): 1496–501. doi: 10.1002/jcph.1655.Rosen R, Brown C, Heiman J et al. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26(2): 191–208. doi: 10.1080/009262300278597.Rosen R, Brown C, Heiman J et al. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26(2): 191–208. doi: 10.1080/009262300278597.Beck AT, Steer RA, Brown GK. Manual for the Beck depression inventory-II. San Antonio, TX: Psychological Corporation. 1996; 38 pp. ISBN-10: 0158018389.Beck AT, Steer RA, Brown GK. Manual for the Beck depression inventory-II. San Antonio, TX: Psychological Corporation. 1996; 38 pp. ISBN-10: 0158018389.Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, Okopien B. Sexual function and depressive symptoms in young women with elevated macroprolactin content: A pilot study. Endocrine. 2016; 53(1): 291–98. doi: 10.1007/s12020-016-0898-5.Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, Okopien B. Sexual function and depressive symptoms in young women with elevated macroprolactin content: A pilot study. Endocrine. 2016; 53(1): 291–98. doi: 10.1007/s12020-016-0898-5.Malarkey WB, Jackson R, Wortsman J. Long-term assessment of patients with macroprolactinemia. Fertil Steril. 1988; 50(3): 413–18. doi: 10.1016/S0015-0282(16)60124-3.Malarkey WB, Jackson R, Wortsman J. Long-term assessment of patients with macroprolactinemia. Fertil Steril. 1988; 50(3): 413–18. doi: 10.1016/S0015-0282(16)60124-3.Lewandowski KC, Gąsior-Perczak D, Kowalska A, Lewinski A. Prevalence of macroprolactinaemia in regularly menstruating women with non-toxic goitre or autoimmune thyroid disease. Thyroid Res. 2012; 5(1): 20. doi: 10.1186/1756-6614-5-20.Lewandowski KC, Gąsior-Perczak D, Kowalska A, Lewinski A. Prevalence of macroprolactinaemia in regularly menstruating women with non-toxic goitre or autoimmune thyroid disease. Thyroid Res. 2012; 5(1): 20. doi: 10.1186/1756-6614-5-20.Guclu M, Cander S, Kiyici S et al. Serum macroprolactin levels in pregnancy and association with thyroid autoimmunity. BMC Endocr Disord. 2015; 15: 31. doi: 10.1186/s12902-015-0025-2.Guclu M, Cander S, Kiyici S et al. Serum macroprolactin levels in pregnancy and association with thyroid autoimmunity. BMC Endocr Disord. 2015; 15: 31. doi: 10.1186/s12902-015-0025-2.Leanos-Miranda A, Pascoe-Lira D, Chavez-Rueda KA, Blanco-Favela F. Detection of macroprolactinemia with the polyethylene glycol precipitation test in systemic lupus erythematosus patients with hyperprolactinemia. Lupus. 2001; 10(5): 340–45. doi: 10.1191/096120301672772070.Leanos-Miranda A, Pascoe-Lira D, Chavez-Rueda KA, Blanco-Favela F. Detection of macroprolactinemia with the polyethylene glycol precipitation test in systemic lupus erythematosus patients with hyperprolactinemia. Lupus. 2001; 10(5): 340–45. doi: 10.1191/096120301672772070.Kramer CK, Tourinho TF, de Castro WP, da Costa Oliveira M. Association between systemic lupus erythematosus, rheumatoid arthritis, hyperprolactinemia and thyroid autoantibodies. Arch Med Res. 2005; 36(1): 54–58. doi: 10.1016/j.arcmed.2004.11.007.Kramer CK, Tourinho TF, de Castro WP, da Costa Oliveira M. Association between systemic lupus erythematosus, rheumatoid arthritis, hyperprolactinemia and thyroid autoantibodies. Arch Med Res. 2005; 36(1): 54–58. doi: 10.1016/j.arcmed.2004.11.007.Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29(2): 288–91.Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29(2): 288–91.Toffoli Ribeiro C, Louzada Junior P, de Sa MF. Correlation between systemic lupus erythematosus activity and plasma levels of monomeric prolactin and macroprolactin. Endocr Metab Immune Disord Drug Targets. 2016; 16(1): 21–27. doi: 10.2174/1871530315666151020101518.Toffoli Ribeiro C, Louzada Junior P, de Sa MF. Correlation between systemic lupus erythematosus activity and plasma levels of monomeric prolactin and macroprolactin. Endocr Metab Immune Disord Drug Targets. 2016; 16(1): 21–27. doi: 10.2174/1871530315666151020101518.Jokar M, Tayyebi Maybodi N, Amini A, Hatef Fard M. Prolactin and macroprolactin in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases. 2008; 11(3): 257–62. doi: 10.1111/j.1756-185X.2008.00378.x.Jokar M, Tayyebi Maybodi N, Amini A, Hatef Fard M. Prolactin and macroprolactin in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases. 2008; 11(3): 257–62. doi: 10.1111/j.1756-185X.2008.00378.x.Kavanagh-Wright L, Smith TP, Gibney J, McKenna TJ. Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients. Clin Endocrinol (Oxf). 2009; 70(4): 599–605. doi: 10.1111/j.1365-2265.2008.03402.x.Kavanagh-Wright L, Smith TP, Gibney J, McKenna TJ. Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients. Clin Endocrinol (Oxf). 2009; 70(4): 599–605. doi: 10.1111/j.1365-2265.2008.03402.x.Рымар О.Д., Воевода С.М., Шахтшнейдер Е.В. с соавт. Частота метаболического синдрома и его отдельных компонентов у женщин 25–45 лет в зависимости от уровня пролактина. Ожирение и метаболизм. 2021; 18(2): 180–189. doi: 10.14341/omet12475.Рымар О.Д., Воевода С.М., Шахтшнейдер Е.В. с соавт. Частота метаболического синдрома и его отдельных компонентов у женщин 25–45 лет в зависимости от уровня пролактина. Ожирение и метаболизм. 2021; 18(2): 180–189. doi: 10.14341/omet12475.Krysiak R, Szkrobka W, Okopien B. Cardiometabolic risk factors in men with elevated macroprolactin content: A pilot study. Exp Clin Endocrinol Diabetes. 2021; 129(1): 7–13. doi: 10.1055/a-0902-4439.Krysiak R, Szkrobka W, Okopien B. Cardiometabolic risk factors in men with elevated macroprolactin content: A pilot study. Exp Clin Endocrinol Diabetes. 2021; 129(1): 7–13. doi: 10.1055/a-0902-4439.Krysiak R, Marek B, Okopien B. Cardiometabolic risk factors in young women with macroprolactinaemia. Endokrynol Pol. 2019; 70(4): 336–41. doi: 10.5603/EP.a2019.0013.Krysiak R, Marek B, Okopien B. Cardiometabolic risk factors in young women with macroprolactinaemia. Endokrynol Pol. 2019; 70(4): 336–41. doi: 10.5603/EP.a2019.0013.Krysiak R., Kowalska B., Szkrobka W., Okopien B. The association between macroprolactin levels and vitamin D status in premenopausal women with macroprolactinemia: A pilot study. Exp Clin Endocrinol Diabetes. 2015; 123(8): 446–50. doi: 10.1055/s-0035-1555877.Krysiak R., Kowalska B., Szkrobka W., Okopien B. The association between macroprolactin levels and vitamin D status in premenopausal women with macroprolactinemia: A pilot study. Exp Clin Endocrinol Diabetes. 2015; 123(8): 446–50. doi: 10.1055/s-0035-1555877.Landberg E, Dahlstrom U, Alehagen U. Serum prolactin and macroprolactin in heart failure: No relation to established laboratory or clinical parameters. Ann Clin Biochem. 2011; 48(Pt 1): 51–56. doi: 10.1258/acb.2010.010164.Landberg E, Dahlstrom U, Alehagen U. Serum prolactin and macroprolactin in heart failure: No relation to established laboratory or clinical parameters. Ann Clin Biochem. 2011; 48(Pt 1): 51–56. doi: 10.1258/acb.2010.010164.Anaforoglu I, Ertorer ME, Kozanoglu I et al. Macroprolactinemia, like hyperprolactinemia, may promote platelet activation [published correction appears in Endocrine. 2010; 37(2): 301–2. Endocrine. 2010; 37(2): 294–300. doi: 10.1007/s12020-009-9304-x.Anaforoglu I, Ertorer ME, Kozanoglu I et al. Macroprolactinemia, like hyperprolactinemia, may promote platelet activation [published correction appears in Endocrine. 2010; 37(2): 301–2. Endocrine. 2010; 37(2): 294–300. doi: 10.1007/s12020-009-9304-x.Delcour C, Robin G, Young J, Dewailly D. PCOS and hyperprolactinemia: What do we know in 2019? Clin Med Insights Reprod Health. 2019; 13: 1179558119871921. doi:10.1177/1179558119871921.Delcour C, Robin G, Young J, Dewailly D. PCOS and hyperprolactinemia: What do we know in 2019? Clin Med Insights Reprod Health. 2019; 13: 1179558119871921. doi:10.1177/1179558119871921.Davoudi Z, Araghi F, Vahedi M et al. Prolactin level in polycystic ovary syndrome (PCOS): An approach to the diagnosis and management. Acta Biomed. 2021; 92(5): e2021291. doi:10.23750/abm.v92i5.9866.Davoudi Z, Araghi F, Vahedi M et al. Prolactin level in polycystic ovary syndrome (PCOS): An approach to the diagnosis and management. Acta Biomed. 2021; 92(5): e2021291. doi:10.23750/abm.v92i5.9866.Hayashida A, Marcondes JA, Soares JM Jr et al. Evaluation of macroprolactinemia in 259 women under investigation for polycystic ovary syndrome. Clin Endocrinol (Oxf). 2014; 80(4): 616–18. doi:10.1111/cen.12266.Hayashida A, Marcondes JA, Soares JM Jr et al. Evaluation of macroprolactinemia in 259 women under investigation for polycystic ovary syndrome. Clin Endocrinol (Oxf). 2014; 80(4): 616–18. doi:10.1111/cen.12266.

The authors declare that there are no conflicts of interest present.